A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

Clinical trial NCT06614907 · COMPLETED

Trial details

NCT number: NCT06614907
Sponsor: Qilu Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2024-08-31
Primary completion: 2024-11-15
Enrollment: 198

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.